| 前收市價 | 43.05 |
| 開市 | 43.05 |
| 買盤 | 36.50 |
| 賣出價 | 39.80 |
| 拍板 | 120.00 |
| 到期日 | 2024-07-19 |
| 今日波幅 | 43.05 - 43.05 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 10 |
Investor's Business DailyAlnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
BloombergAlnylam Shares Soar After Drug Meets Goal in Heart Disease Trial
(Bloomberg) -- Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product. Most Read from BloombergHow Long Can High Rates Last? Bond Markets Say Maybe ForeverNvidia Sales Grow So Fast That Wall Street Can’t Keep UpJain Raises $5.3 Billion in Biggest Hedge Fund Debut Since 2018Russia Is Storing Up a Crime Wave When Its War on Ukraine EndsYen Is Under Pres
ZacksAlnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
